At 11.0% CAGR, Middle East & Africa Bioprocessing Market is Projected to be Worth US$ 725.54 Million by 2031, says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa bioprocessing market was valued at US$ 314.37 million in 2023 and is expected to reach US$ 725.54 million by 2031, registering a CAGR of 11.0% from 2023 to 2031. Increasing prevalences of chronic diseases and proliferating demand for personalized medicine are among the critical factors attributed to drive the Middle East & Africa bioprocessing market growth.

The sedentary life of older people has boosted the prevalence of lifestyle disorders, such as obesity and diabetes. Inherited genes can also express these conditions along with other health concerns such as cardiovascular disease (CVDs), Alzheimer's disease, and depression. According to WHO, in 2020, there were more adults over 60 than children under five. The percentage of the global population over 60 will almost double from 12% to 22% between 2015 and 2050. Numerous chronic disorders, such as dementia, osteoarthritis, cancer, stroke, and cardiovascular disease, are known to be associated with aging. CVDs, such as angina pectoris, atherosclerosis, and acute myocardial infarction caused because of hectic lifestyles, are among the significant causes of mortality across the world. As per the World Heart Foundation, mortality caused due to CVD has surged by 60% over the past 30 years (1990-2020). 20.5 million deaths were recorded in 2021 due to CVDs. Diabetes is one of the life-threatening chronic diseases with no functional cure. Diabetes of all types can cause various complications in different body parts, thereby increasing the overall risk of death. According to the International Diabetes Federation. Additionally, 425 million people had diabetes in 2017, and the number is anticipated to reach 629 million by 2045 worldwide, which is an increase of about 35%. As per the Global Cancer Observatory (GLOBOCAN) estimates published in 2020, 19.3 million cancer cases were reported across the world. Similarly, as per the World Health Organization data published in February 2022, ~10 million people across the world have succumbed to death due to cancer. An upsurge in the incidence of cancer indicates the need for innovative cancer treatments. Monoclonal antibodies represent a promising class of targeted anticancer agents that enhance the natural ability of immune systems to suppress cancer cell activity and eliminate cancer cells. Antibody-drug conjugates (ADCs) have also shown promising results in cancer treatment.

The recognition of biosimilars as efficient and safe by specialists, patients, primary care clinicians, and other healthcare professionals is propelling its demand. Biosimilars have been proven to improve the quality of life for millions of patients. They are impactful and cost-effective options for treating many diseases, including chronic skin conditions (such as psoriasis and atopic dermatitis), bowel diseases (such as Crohn's disease, irritable bowel syndrome, and colitis), diabetes, autoimmune disease, cancer, kidney conditions, and arthritis. Biosimilar developers are adopting advanced bioprocessing technologies to achieve lower manufacturing costs, which is an important factor in determining the final consumer prices. Nearly all biosimilar developers are using modern, cutting-edge bioprocessing techniques. Therefore, with the growing prevalence of chronic diseases, the demand for biosimilars to treat life-threatening illnesses is spurring, thereby propelling the demand for bioprocessing.

On the contrary, stringent regulatory policies and limitations associated with bioprocessing hamper the growth of Middle East & Africa bioprocessing market.

Based on product, the Middle East & Africa bioprocessing market is bifurcated into instruments and consumables & accessories. The instruments segment held 66.8% market share in 2023, amassing US$ 209.85 million. It is projected to garner US$ 501.83 million by 2031 to register 11.5% CAGR during 2023-2031. Furthermore, the instruments segment is sub segmented into filtration devices, bioreactors, chromatography systems, centrifuge, drying devices, and others. Additionally, the bioreactors subsegment is categorized into pilot scale, full scale, and laboratory scale. Furthermore, the subsegment chromatography systems is segmented into liquid chromatography, gas chromatography, and others. Additionally, the consumables & accessories segment is sub segmented into reagents, cell culture media, chromatography resins, and others.

In terms of scale of operation, the Middle East & Africa bioprocessing market is bifurcated into commercial operations and clinical operations. The commercial operations segment held 81.9% share of Middle East & Africa bioprocessing market in 2023, amassing US$ 257.48 million. It is anticipated to garner US$ 611.51 million by 2031 to expand at 11.4% CAGR during 2023-2031.

By process, the Middle East & Africa bioprocessing market is bifurcated into downstream bioprocess and upstream bioprocess. The downstream bioprocess aids segment held 60.8% share of Middle East & Africa bioprocessing market in 2023, amassing US$ 191.27 million. It is projected to garner US$ 451.27 million by 2031 to expand at 11.3% CAGR from 2023 to 2031.

Based on application, the Middle East & Africa bioprocessing market is categorized into monoclonal antibodies, vaccines, recombinant protein, cell & gene therapy, and others. The monoclonal antibodies segment held 37.9% share of Middle East & Africa bioprocessing market in 2023, amassing US$ 119.29 million. It is predicted to garner US$ 257.36 million by 2031 to expand at 10.1% CAGR between 2023 and 2031.

In terms of end user, the Middle East & Africa bioprocessing market is categorized into biopharmaceutical companies, contract manufacturing organization, and others. The biopharmaceutical companies held 52.9% share of Middle East & Africa bioprocessing market in 2023, amassing US$ 166.31 million. It is estimated to garner US$ 389.57 million by 2031 to expand at 11.2% CAGR during 2023-2031.

By country, the Middle East & Africa bioprocessing market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 40.0% share of Middle East & Africa bioprocessing market in 2023. It was assessed at US$ 125.88 million in 2023 and is likely to hit US$ 299.79 million by 2031, registering a CAGR of 11.5% during 2023-2031.

Key players operating in the Middle East & Africa bioprocessing market are Getinge AB, Thermo Fisher Scientific Inc, Sartorius AG, Corning Inc, Bio-Rad Laboratories Inc, Merck KGaA, 3M Co, Eppendorf SE, Agilent Technologies Inc, and Cytiva US LLC, among others.

• In November 2023, 3M Co revealed the newest model in its line of chromatographic clarifiers. For the purpose of separating monoclonal antibodies, recombinant proteins, and biologics, Harvest RC Chromatographic Clarifier, BT500 is a 500 mL chromatographic clarifier designed for single use. Based on 5-8% packed cell volume (PCV) culture, the business claims that the BT500 can generate predictive yield samples in 10 minutes. Customers seeking to optimize productivity in the laboratory can now better meet the rapidly increasing demands of the industry with the addition of 3M Harvest RC Chromatographic Clarifier, BT500, to their product line.
  
  
• In February 2024, The Eppendorf Group is growing by establishing a new site in South Africa. A sophisticated pipette calibration laboratory with a service workshop and a customer experience center featuring Eppendorf equipment are among the amenities offered by the branch office, which is situated in Johannesburg's Waterfall City economic center. This location provides top-notch laboratory services, such as instrument maintenance and customer training.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com